This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pfaller, M. A.
Right arrow Articles by Diekema, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pfaller, M. A.
Right arrow Articles by Diekema, D. J.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Yeast Infections

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, May 2003, p. 2176-2179, Vol. 41, No. 5
0095-1137/03/$08.00+0     DOI: 10.1128/JCM.41.5.2176-2179.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Variation in Susceptibility of Bloodstream Isolates of Candida glabrata to Fluconazole According to Patient Age and Geographic Location

M. A. Pfaller,1,2* S. A. Messer,1 L. Boyken,1 S. Tendolkar,1 R. J. Hollis,1 and D. J. Diekema1,3

Departments of Pathology,1 Medicine, Roy J. and Lucille A. Carver College of Medicine,3 Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, Iowa 522422

Received 18 November 2002/ Returned for modification 12 January 2003/ Accepted 8 February 2003

We examined the susceptibilities to fluconazole of 559 bloodstream infection isolates of Candida glabrata and grouped the isolates by patient age and geographic location within the United States. Susceptibility of C. glabrata to fluconazole was lowest in the Pacific (44%) and East South Central (47%) regions and was highest in the West South Central region (82%) (regions are as designated by the U.S. Bureau of the Census). Isolates from pediatric patients were virtually all susceptible to fluconazole, whereas the highest frequency of resistance was observed in isolates from patients 16 to 64 years of age.

* Corresponding author. Mailing address: Medical Microbiology Division, C606 GH, Department of Pathology, University of Iowa College of Medicine, Iowa City, IA 52242. Phone: (319) 384-9566. Fax: (319) 356-4916. E-mail: michael-pfaller{at}uiowa.edu.

Journal of Clinical Microbiology, May 2003, p. 2176-2179, Vol. 41, No. 5
0095-1137/03/$08.00+0     DOI: 10.1128/JCM.41.5.2176-2179.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Pfaller, M. A., Messer, S. A., Hollis, R. J., Boyken, L., Tendolkar, S., Kroeger, J., Diekema, D. J. (2009). Variation in Susceptibility of Bloodstream Isolates of Candida glabrata to Fluconazole According to Patient Age and Geographic Location in the United States in 2001 to 2007. J. Clin. Microbiol. 47: 3185-3190 [Abstract] [Full Text]  
  • Schuster, M., Panzer, H., Edwards, J. (2009). Empirical Use of Fluconazole in Critically Ill Patients: Good Study, but What Was the Hold-up?. ANN INTERN MED 150: 59-60 [Full Text]  
  • Tumbarello, M., Sanguinetti, M., Trecarichi, E. M., La Sorda, M., Rossi, M., de Carolis, E., de Gaetano Donati, K., Fadda, G., Cauda, R., Posteraro, B. (2008). Fungaemia caused by Candida glabrata with reduced susceptibility to fluconazole due to altered gene expression: risk factors, antifungal treatment and outcome. J Antimicrob Chemother 62: 1379-1385 [Abstract] [Full Text]  
  • Gonzalez, G. M., Elizondo, M., Ayala, J. (2008). Trends in Species Distribution and Susceptibility of Bloodstream Isolates of Candida Collected in Monterrey, Mexico, to Seven Antifungal Agents: Results of a 3-Year (2004 to 2007) Surveillance Study. J. Clin. Microbiol. 46: 2902-2905 [Abstract] [Full Text]  
  • Foster, N., Symes, C., Barton, R., Hobson, R. (2007). Rapid identification of Candida glabrata in Candida bloodstream infections. J Med Microbiol 56: 1639-1643 [Abstract] [Full Text]  
  • Pfaller, M. A., Diekema, D. J. (2007). Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem. Clin. Microbiol. Rev. 20: 133-163 [Abstract] [Full Text]  
  • Forrest, G. N., Mankes, K., Jabra-Rizk, M. A., Weekes, E., Johnson, J. K., Lincalis, D. P., Venezia, R. A. (2006). Peptide Nucleic Acid Fluorescence In Situ Hybridization-Based Identification of Candida albicans and Its Impact on Mortality and Antifungal Therapy Costs.. J. Clin. Microbiol. 44: 3381-3383 [Abstract] [Full Text]  
  • Magill, S. S., Shields, C., Sears, C. L., Choti, M., Merz, W. G. (2006). Triazole Cross-Resistance among Candida spp.: Case Report, Occurrence among Bloodstream Isolates, and Implications for Antifungal Therapy. J. Clin. Microbiol. 44: 529-535 [Abstract] [Full Text]  
  • Sanguinetti, M., Posteraro, B., Fiori, B., Ranno, S., Torelli, R., Fadda, G. (2005). Mechanisms of Azole Resistance in Clinical Isolates of Candida glabrata Collected during a Hospital Survey of Antifungal Resistance. Antimicrob. Agents Chemother. 49: 668-679 [Abstract] [Full Text]  
  • Rudensky, B., Broidie, E., Yinnon, A. M., Weitzman, T., Paz, E., Keller, N., Raveh, D. (2005). Rapid flow-cytometric susceptibility testing of Candida species. J Antimicrob Chemother 55: 106-109 [Abstract] [Full Text]  
  • Weig, M., Jansch, L., Gross, U., De Koster, C. G., Klis, F. M., De Groot, P. W. J. (2004). Systematic identification in silico of covalently bound cell wall proteins and analysis of protein-polysaccharide linkages of the human pathogen Candida glabrata. Microbiology 150: 3129-3144 [Abstract] [Full Text]  
  • Stoyan, T., Carbon, J. (2004). Inner Kinetochore of the Pathogenic Yeast Candida glabrata. Eukaryot Cell 3: 1154-1163 [Abstract] [Full Text]  
  • Barchiesi, F., Spreghini, E., Maracci, M., Fothergill, A. W., Baldassarri, I., Rinaldi, M. G., Scalise, G. (2004). In Vitro Activities of Voriconazole in Combination with Three Other Antifungal Agents against Candida glabrata. Antimicrob. Agents Chemother. 48: 3317-3322 [Abstract] [Full Text]  
  • Pfaller, M. A., Messer, S. A., Boyken, L., Tendolkar, S., Hollis, R. J., Diekema, D. J. (2004). Geographic Variation in the Susceptibilities of Invasive Isolates of Candida glabrata to Seven Systemically Active Antifungal Agents: a Global Assessment from the ARTEMIS Antifungal Surveillance Program Conducted in 2001 and 2002. J. Clin. Microbiol. 42: 3142-3146 [Abstract] [Full Text]  
  • Pfaller, M. A., Messer, S. A., Boyken, L., Rice, C., Tendolkar, S., Hollis, R. J., Diekema, D. J. (2003). Caspofungin Activity against Clinical Isolates of Fluconazole-Resistant Candida. J. Clin. Microbiol. 41: 5729-5731 [Abstract] [Full Text]  
  • Hsu, M.-C., Chen, K.-W., Lo, H.-J., Chen, Y.-C., Liao, M.-H., Lin, Y.-H., Li, S.-Y. (2003). Species identification of medically important fungi by use of real-time LightCycler PCR. J Med Microbiol 52: 1071-1076 [Abstract] [Full Text]  
  • Ostrosky-Zeichner, L., Rex, J. H., Pappas, P. G., Hamill, R. J., Larsen, R. A., Horowitz, H. W., Powderly, W. G., Hyslop, N., Kauffman, C. A., Cleary, J., Mangino, J. E., Lee, J. (2003). Antifungal Susceptibility Survey of 2,000 Bloodstream Candida Isolates in the United States. Antimicrob. Agents Chemother. 47: 3149-3154 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»